Martin R Berger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4207322/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Conditional knockdown of integrin beta-3 reveals its involvement in osteolytic and soft tissue lesions of breast cancer skeletal metastasis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 361-371.	1.2	20
2	A subgroup of lactosyl-Sepharose binding proteins requires calcium for affinity and galactose for anti-proliferation. Chemico-Biological Interactions, 2021, 334, 109354.	1.7	4
3	Antineoplastic effects of targeting CCR5 and its therapeutic potential for colorectal cancer liver metastasis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 73-91.	1.2	16
4	Discovery of Novel CCR5 Ligands as Anticolorectal Cancer Agents by Sequential Virtual Screening. ACS Omega, 2021, 6, 10921-10935.	1.6	7
5	Dual Akt and Bcl-2 inhibition induces cell-type specific modulation of apoptotic and autophagic signaling in castration resistant prostate cancer cell lines. Molecular Biology Reports, 2021, 48, 7755-7765.	1.0	1
6	Riproximin Exhibits Diversity in Sugar Binding, and Modulates some Metastasis-Related Proteins with Lectin like Properties in Pancreatic Ductal Adenocarcinoma. Frontiers in Pharmacology, 2020, 11, 549804.	1.6	7
7	Modulation of the Endothelin System in Colorectal Cancer Liver Metastasis: Influence of Epigenetic Mechanisms?. Frontiers in Pharmacology, 2020, 11, 180.	1.6	5
8	Lactosyl-sepharose binding proteins from pancreatic cancer cells show differential expression in primary and metastatic organs. Experimental Biology and Medicine, 2020, 245, 631-643.	1.1	4
9	The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction. Cancer Letters, 2020, 474, 82-93.	3.2	23
10	Multiple Facets of Autophagy and the Emerging Role of Alkylphosphocholines as Autophagy Modulators. Frontiers in Pharmacology, 2020, 11, 547.	1.6	25
11	Optineurin downregulation induces endoplasmic reticulum stress, chaperone-mediated autophagy, and apoptosis in pancreatic cancer cells. Cell Death Discovery, 2019, 5, 128.	2.0	19
12	Conditional Knockdown of Osteopontin Inhibits Breast Cancer Skeletal Metastasis. International Journal of Molecular Sciences, 2019, 20, 4918.	1.8	22
13	Experimental Results Help Shape the Development of Personalized Medicine in Colorectal Cancer. , 2019, , .		0
14	ABT-737 and erufosine combination against castration-resistant prostate cancer. Anti-Cancer Drugs, 2019, 30, 383-393.	0.7	9
15	CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer. Cellular Oncology (Dordrecht), 2019, 42, 93-106.	2.1	44
16	Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 66-91.	0.9	14
17	Induction of ER and mitochondrial stress by the alkylphosphocholine erufosine in oral squamous cell carcinoma cells. Cell Death and Disease, 2018, 9, 296.	2.7	32
18	IDK1 is a rat monoclonal antibody against hypoglycosylated bone sialoprotein with application as biomarker and therapeutic agent in breast cancer skeletal metastasis. Journal of Pathology: Clinical Research, 2018, 4, 55-68.	1.3	13

#	Article	IF	CITATIONS
19	The expression of genes contributing to pancreatic adenocarcinoma progression is influenced by the respective environment. Genes and Cancer, 2018, 9, 114-129.	0.6	13
20	Pancreatic carcinoma cells colonizing the liver modulate the expression of their extracellular matrix genes. Genes and Cancer, 2018, 9, 215-231.	0.6	6
21	Upregulation of cell cycle genes in head and neck cancer patients may be antagonized by erufosine's down regulation of cell cycle processes in OSCC cells. Oncotarget, 2018, 9, 5797-5810.	0.8	14
22	Erufosine increases RhoB expression in oral squamous carcinoma cells independent of its tumor suppressive mode of action - a short report. Cellular Oncology (Dordrecht), 2017, 40, 89-96.	2.1	11
23	The ribosome inhibiting protein riproximin shows antineoplastic activity in experimental pancreatic cancer liver metastasis. Oncology Letters, 2017, 15, 1441-1448.	0.8	7
24	Investigation of Metastasis-Related Genes: A Rat Model Mimicking Liver Metastasis of Colorectal Carcinoma. Frontiers in Oncology, 2017, 7, 152.	1.3	2
25	The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis. Tumor Biology, 2016, 37, 2461-2471.	0.8	35
26	Riproximin modulates multiple signaling cascades leading to cytostatic and apoptotic effects in human breast cancer cells. Journal of Cancer Research and Clinical Oncology, 2016, 142, 135-147.	1.2	26
27	Riproximin: A type II ribosome inactivating protein with anti-neoplastic potential induces IL24/MDA-7 and GADD genes in colorectal cancer cell lines. International Journal of Oncology, 2015, 47, 981-990.	1.4	10
28	Antitumor Lipids—Structure, Functions, and Medical Applications. Advances in Protein Chemistry and Structural Biology, 2015, 101, 27-66.	1.0	31
29	CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells. Medical Oncology, 2015, 32, 158.	1.2	40
30	Reduced Expression of the Retinoblastoma Protein Shows That the Related Signaling Pathway Is Essential for Mediating the Antineoplastic Activity of Erufosine. PLoS ONE, 2014, 9, e100950.	1.1	10
31	Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL. Cancer Biology and Therapy, 2014, 15, 1185-1197.	1.5	11
32	Erufosine Induces Autophagy and Apoptosis in Oral Squamous Cell Carcinoma. , 2014, , 229-245.		1
33	Alkylphosphocholines and curcumin induce programmed cell death in cutaneous T-cell lymphoma cell lines. Leukemia Research, 2014, 38, 49-56.	0.4	22
34	Riproximin is a recently discovered type II ribosome inactivating protein with potential for treating cancer. Biotechnology Advances, 2014, 32, 1077-1090.	6.0	24
35	Differential effects of erufosine on proliferation, wound healing and apoptosis in colorectal cancer cell lines. Oncology Reports, 2014, 31, 1407-1416.	1.2	17
36	Sustained conditional knockdown reveals intracellular bone sialoprotein as essential for breast cancer skeletal metastasis. Oncotarget, 2014, 5, 5510-5522.	0.8	28

#	Article	IF	CITATIONS
37	SIBLINGs and SPARC families: Their emerging roles in pancreatic cancer. World Journal of Gastroenterology, 2014, 20, 14747.	1.4	21
38	Effect of Erufosine on the Reorganization of Cytoskeleton and Cell Death in Adherent Tumor and Non-Tumorigenic Cells. Biotechnology and Biotechnological Equipment, 2013, 27, 3695-3699.	0.5	7
39	Evaluation of Riproximin Binding Properties Reveals a Novel Mechanism for Cellular Targeting*. Journal of Biological Chemistry, 2012, 287, 35873-35886.	1.6	17
40	Few genes are associated with the capability of pancreatic ductal adenocarcinoma cells to grow in the liver of nude rats. Oncology Reports, 2012, 28, 2177-2187.	1.2	18
41	Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1909-1917.	1.2	31
42	Purification and characterization of riproximin from Ximenia americana fruit kernels. Protein Expression and Purification, 2012, 82, 97-105.	0.6	21
43	Multi-modal Imaging of Angiogenesis in a Nude Rat Model of Breast Cancer Bone Metastasis Using Magnetic Resonance Imaging, Volumetric Computed Tomography and Ultrasound. Journal of Visualized Experiments, 2012, , e4178.	0.2	10
44	Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt–mTOR signaling pathway in oral squamous cell carcinoma. Cancer Letters, 2012, 319, 39-48.	3.2	59
45	Prognostic value of tumor progression-related gene expression in colorectal cancer patients. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1631-1640.	1.2	11
46	Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions. Clinical and Experimental Metastasis, 2012, 29, 441-456.	1.7	33
47	Sequential biphasic changes in claudin1 and claudin4 expression are correlated to colorectal cancer progression and liver metastasis. Journal of Cellular and Molecular Medicine, 2012, 16, 260-272.	1.6	30
48	Disseminated colorectal tumor cells in organs prone to metastasis detected by new double enriched nested-PCR in comparison with recognized assays. Oncology Reports, 2011, 25, 1421-9.	1.2	1
49	Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1139-1145.	1.2	8
50	Erucylphospho-N,N,N-trimethylpropylammonium (erufosine) is a potential antimyeloma drug devoid of myelotoxicity. Cancer Chemotherapy and Pharmacology, 2011, 67, 13-25.	1.1	32
51	Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCEâ€MRI in a longitudinal <i>in vivo</i> study. International Journal of Cancer, 2011, 128, 2453-2462.	2.3	78
52	The insulin-like growth factor binding proteins 3 and 7 are associated with colorectal cancer and liver metastasis. Cancer Biology and Therapy, 2011, 12, 69-79.	1.5	51
53	Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. International Journal of Cancer, 2010, 126, 1749-1760.	2.3	48
54	K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRα in colorectal cancer. International Journal of Colorectal Disease, 2010, 25, 181-186.	1.0	21

#	Article	IF	CITATIONS
55	Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration. International Journal of Colorectal Disease, 2010, 25, 417-424.	1.0	27
56	Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines. Cancer Biology and Therapy, 2010, 10, 54-64.	1.5	34
57	Biodistribution of antisense nanoparticles in mammary carcinoma rat model. Drug Delivery, 2010, 17, 408-418.	2.5	14
58	Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis. European Journal of Radiology, 2010, 73, 280-287.	1.2	57
59	Regulation of osteopontin and related proteins in rat CC531 colorectal cancer cells. International Journal of Oncology, 2010, 37, 249-56.	3.9	9
60	Erucylphosphoâ€ <i>N,N,N</i> â€ŧrimethylpropylammonium Shows Substantial Cytotoxicity in Multiple Myeloma Cells. Annals of the New York Academy of Sciences, 2009, 1171, 350-358.	1.8	10
61	Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin. Clinical and Experimental Metastasis, 2008, 25, 273-282.	1.7	40
62	Bevacizumab Inhibits Breast Cancer-Induced Osteolysis, Surrounding Soft Tissue Metastasis, and Angiogenesis in Rats as Visualized by VCT and MRI. Neoplasia, 2008, 10, 511-520.	2.3	51
63	The expression level of the tumor suppressor retinoblastoma protein (Rb) influences the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropylammonium (ErPC3). Cancer Biology and Therapy, 2007, 6, 930-935.	1.5	9
64	Effect of zoledronic acid and an antibody against bone sialoprotein II on MDA-MB-231GFP breast cancer cells inÂvitro and on osteolytic lesions induced inÂvivo by this cell line in nude rats. Clinical and Experimental Metastasis, 2007, 24, 449-459.	1.7	6
65	Miltefosine decreases the cytotoxic effect of Epirubicine and Cyclophosphamide on mouse spermatogenic, thymic and bone marrow cells. Archives of Toxicology, 2006, 80, 27-33.	1.9	6
66	Identification of potent anticancer activity in Ximenia americana aqueous extracts used by African traditional medicine. Toxicology and Applied Pharmacology, 2006, 211, 177-187.	1.3	54
67	Identification and characterization of riproximin, a new type II ribosomeâ€inactivating protein with antineoplastic activity from Ximenia americana. FASEB Journal, 2006, 20, 1194-1196.	0.2	47
68	Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein. International Journal of Oncology, 2006, 28, 573-83.	1.4	14
69	Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. International Journal of Cancer, 2005, 115, 177-186.	2.3	65
70	Molecular detection of clinical colorectal cancer metastasis: how should multiple markers be put to use?. International Journal of Colorectal Disease, 2005, 20, 137-146.	1.0	40
71	Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine. Journal of Cancer Research and Clinical Oncology, 2005, 131, 289-299.	1.2	10
72	Detection of Isolated Tumor Cells by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism for K-ras Mutations in Tissue Samples of 199 Colorectal Cancer Patients. Clinical Cancer Research, 2004, 10, 641-650.	3.2	50

#	Article	IF	CITATIONS
73	Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Therapy, 2004, 11, 109-120.	2.2	67
74	Chemoembolization of rat liver metastasis with irinotecan and quantification of tumor cell reduction. Journal of Cancer Research and Clinical Oncology, 2004, 130, 203-210.	1.2	12
75	Prognostic value of disseminated colorectal tumor cells in the liver: results of follow-up examinations. International Journal of Colorectal Disease, 2004, 19, 380-386.	1.0	26
76	Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. International Journal of Oncology, 2004, 24, 1235-44.	1.4	20
77	Chemoembolization of rat liver metastasis with microspheres and gemcitabine followed by evaluation of tumor cell load by chemiluminescence. Oncology Reports, 2004, 11, 1107-13.	1.2	5
78	K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients. International Journal of Oncology, 2004, 24, 1537-44.	1.4	6
79	Induction of Apoptosis by Erucylphospho-N,N,N-trimethylammonium Is Associated with Changes in Signal Molecule Expressionand Location. Annals of the New York Academy of Sciences, 2003, 1010, 307-310.	1.8	19
80	Superiority of combined chemo-embolization and portal infusion with 5-fluorouracil over locoregional infusion concepts in Novikoff hepatoma-bearing rats. Journal of Cancer Research and Clinical Oncology, 2003, 129, 655-661.	1.2	2
81	Cytokeratin 20 and guanylyl cyclase C mRNA is largely present in lymph node and liver specimens of colorectal cancer patients. International Journal of Cancer, 2003, 107, 617-628.	2.3	21
82	Hepatic disseminated tumor cells in colorectal cancer UICC stage 4 patients: prognostic implications. International Journal of Oncology, 2003, 23, 791-6.	1.4	6
83	Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells. Cancer Letters, 2002, 182, 163-174.	3.2	37
84	Combination with an antisense oligonucleotide synergistically improves the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropylammonium in chronic myeloid leukemia cell lines. Molecular Cancer Therapeutics, 2002, 1, 877-84.	1.9	11
85	BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines. British Journal of Haematology, 1999, 107, 365-374.	1.2	140
86	Quantitative detection of lac-Z-transfected CC531 colon carcinoma cells in an orthotopic rat liver metastasis model. Clinical and Experimental Metastasis, 1999, 17, 369-376.	1.7	18
87	Human urinary bladder carcinoma cell lines respond to treatment with alkylphosphocholines. Cancer Letters, 1999, 144, 153-160.	3.2	46
88	Alkylphosphocholines induce apoptosis in HL-60 and U-937 leukemic cells. Cancer Chemotherapy and Pharmacology, 1997, 41, 210-216.	1.1	35
89	Structure-activity relationships of four anti-cancer alkylphosphocholine derivativesIn Vitro andIn Vivo. International Journal of Cancer, 1993, 53, 418-425.	2.3	22
90	Alkylphosphocholines: influence of structural variation on biodistribution at antineoplastically active concentrations. Cancer Chemotherapy and Pharmacology, 1992, 30, 105-112.	1.1	52

1

#	Article	IF	CITATIONS
91	Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties. Cancer Chemotherapy and Pharmacology, 1992, 30, 385-393.	1.1	49

⁹² Early Metastasis in Colorectal Cancer Poses an Option for New Diagnostic and Treatment Strategies. , 0, , .